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Abstract: Omeprazole is a proton-pump inhibitor indicated for gastroesophageal reflux dis-
ease and erosive esophagitis treatment in children. The aim of this review was to evaluate the 
efficacy of delayed-release oral suspension of omeprazole in childhood esophagitis, in terms 
of symptom relief, reduction in reflux index and/or intragastric acidity, and endoscopic and/or 
histological healing. We systematically searched PubMed, Cochrane and EMBASE (1990 
to 2009) and identified 59 potentially relevant articles, but only 12 articles were suitable to 
be included in our analysis. All the studies evaluated symptom relief and reported a median 
relief rate of 80.4% (range 35%–100%). Five studies reported a significant reduction of the 
esophageal reflux index within normal limits (7%) in all children, and 4 studies a significant 
reduction of intra-gastric acidity. The endoscopic healing rate, reported by 9 studies, was 84% 
after 8-week treatment and 95% after 12-week treatment, the latter being significantly higher 
than the histological healing rate (49%). In conclusion, omeprazole given at a dose ranging 
from 0.3 to 3.5 mg/kg once daily (median 1 mg/kg once daily) for at least 12 weeks is highly 
effective in childhood esophagitis.
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Introduction
Gastroesophageal reflux disease and erosive esophagitis 
in pediatric patients: symptoms and therapeutic approaches
Gastroesophageal reflux disease (GERD) is defined as the presence of regurgitation of the 
gastric contents into the esophagus (gastroesophageal reflux) associated with troublesome 
symptoms and/or complications.1 Although different abnormalities in motility variables, 
such as lower esophageal sphincter function, esophageal peristalsis and gastric motor 
activity can contribute to the development of GERD, the degree of esophageal acid 
exposure represents the key factor in its physiopathology. GERD is the most common 
esophageal disorder in childhood and the most frequent reason why infants are referred 
to the pediatric gastroenterologist, affecting as much as 1.8% to 8.2% of the pediatric 
population.2 Presenting features of GERD in infants and children are quite variable and 
follow patterns of gastrointestinal and extra-intestinal manifestations that may vary 
according to age. Patients may be minimally symptomatic, or may exhibit severe esopha-
gitis, bleeding, failure to thrive, or severe respiratory problems. Symptoms of GERD 
may include: regurgitation, persistent vomiting, anorexia/feeding refusal, hypersalivation, 
arching, irritability, persistent crying, abdominal and epigastric pain, heartburn, chest Clinical and Experimental Gastroenterology 2010:3 18
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pain, sleep disturbances,3,4 Sandifer’s syndrome (head turning 
episodes to lengthen the esophagus, repetitive stretching and 
arching, which gives the appearance of seizure/dystonia),5 
dental erosion,6 and many other extra-intestinal manifesta-
tions, mainly respiratory symptoms such as stridor, recurrent 
wheezing, cough, chronic laryngitis, hoarseness, asthma.7–9 
In the more severe forms of GERD esophageal complications 
like erosive or ulcerative esophagitis,10 hemorrhage, stricture, 
Barrett’s esophagus11,12 may be diagnosed.
The main aims of the treatment of GERD in children are 
to relieve symptoms, promote normal growth and prevent 
the afore-mentioned complications. Conservative measures 
include parent reassurance, positioning and altering feed con-
sistency. Treatment options include decreasing intra-gastric 
acidity with antacids, histamine H2 receptor blockers and 
proton pump inhibitors (PPI) and correcting gut motility with 
prokinetics, such as metoclopramide and domperidone. Surgi-
cal approaches like fundoplication are typically reserved to 
children with severe GERD refractory to medical treatment.
A recent systematic review about the pharmacological 
management of GERD in children13 suggested the only safe 
and effective medications are ranitidine and omeprazole and 
probably lansoprazole, being able to promote symptomatic 
relief, and endoscopic and histological healing of esophagi-
tis. In particular, omeprazole is reported to be effective in 
children with GERD refractory to ranitidine treatment and 
should be a first-line treatment in severe esophagitis.13
Omeprazole pharmacology  
and pharmacokinetics
Omeprazole is a PPI blocking the final common pathway of 
acid secretion at the luminal surface of the parietal cell by 
binding to H+K+-ATPase, the so-called “acid pump” or “pro-
ton pump” thereby providing potent suppression of gastric 
acid output. The pro-drug omeprazole is rapidly and almost 
completely absorbed, with peak plasma levels occurring 1 to 
3 hours after ingestion. It is highly (95%) protein-bound and 
rapidly distributed in plasma. The pro-drug is rapidly metabo-
lized by hepatic cytochrome P-450 isoenzyme CYP2C19, 
resulting in a very short plasma half-life of 40 to 60 minutes.14 
Despite its relatively short plasma half-life, clinically adequate 
suppression of acid secretion lasts 12 to 15 hours after a single 
morning dose, because of the covalent binding of omeprazole 
with the parietal cell proton-pumps exposed toward the gastric 
lumen. Thus, the anti-secretory effect of omeprazole is not 
dependent on its plasma concentration at any given time but 
it is directly proportional to the area under the plasma concen-
tration curve (AUC).14 Omeprazole pharmacokinetic studies 
in children shows that younger ones tend to have a higher 
metabolic capacity, resulting in a shorter half life of the drug. 
This may explain the need for higher doses of omeprazole on 
a per kilogram basis in children as compared to adults, and 
even higher in children younger than 6 years of age.15
Omeprazole formulations
Omeprazole is approved for the treatment of GERD and 
erosive esophagitis in children 2 years both by European 
and US indications.
Omeprazole is commercially available in capsules con-
taining enteric-coated, delayed-release granules that should 
not be chewed or crushed because of their acid liability. For 
children who have difficulty in swallowing them, the capsules 
may be opened and the granules sprinkled on applesauce or 
yogurt or dispersed in fruit juice or swallowed immediately 
with water. However, if the child accidentally chews the 
granules, their bitter taste may result in non-compliance with 
refusal of subsequent doses.16 In two studies17,18 omeprazole 
granules have been dissolved in an alkaline vehicle (8.4% 
bicarbonate at a concentration of 2 mg/mL) or in milk. The 
pharmacodynamic resulting from these alternative methods 
of omeprazole administration has been reported to be the 
same as for the intact capsule.19 Use of an extemporaneously 
prepared flavored omeprazole suspension may increase 
compliance and palatability in pediatric patients. However, 
the oral bioavailability of omeprazole in non-proprietary 
formulations has not been accurately assessed yet.
Omeprazole safety and tolerability
The safety and tolerability of omeprazole in both short- and 
long-term use is demonstrated by the scarcity of adverse 
effects in spite of extensive use reported in several studies. 
Most common reported adverse effects have been nausea, 
vomiting, diarrhea, epigastric pain, skin rash, and irrita-
bility17,20–22 but generally no severe enough for patient to 
  discontinue the drug. Only one case of anaphylactic reaction 
due to omeprazole has been reported, in a 14-year-old boy.23 
One recent study reported the association of omeprazole and 
an increased risk of acute gastroenteritis and community-
acquired pneumonia in children.24 Hypergastrinemia,22,25–27 
parietal cell hyperplasia,28 and occasionally gastric polyps29,30 
have also been described in children receiving long-term 
omeprazole therapy. These changes are usually histologi-
cally benign. No statistically significant differences in gastrin 
level according to omeprazole dosage, dosing frequency or 
treatment duration has been reported.21 And no correlation 
between the degree or duration of hypergastrinemia and the Clinical and Experimental Gastroenterology 2010:3 19
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presence of polyps or parietal cell changes. A mild elevation 
in transaminase levels has been reported.25 Therefore, both 
short- and long-term omeprazole therapy appears to be safe 
and well tolerated in children despite some biochemical, 
endoscopic, and histologic changes.20,21
Drug interactions
Omeprazole appears to interact with only one P-450 iso-
enzyme, CYP2C19.31 Thus it is expected to have a narrow 
spectrum of interaction limited to drugs metabolized by this 
enzyme. However, interactions with diazepam, phenytoin, 
warfarin, digoxin, or methotrexate are reported as not 
clinically significant.31–36 There is no effect of omeprazole 
on metabolism of several other drugs tested like theophyl-
line,37,38 propranolol39 or cyclosporine.40
Materials and methods
Literature search
We systematically searched PubMed, Cochrane and EMBASE 
(1990 to 2009) to identify studies evaluating the efficacy of 
delayed release oral suspension of omeprazole for the treatment 
of erosive esophagitis and gastroesophageal reflux in children. 
The search terms used included: “omeprazole”, “gastroesopha-
geal (or gastro-oesophageal) reflux”, “erosive esophagitis 
(or oesophagitis)”, “child$” (or “infant$”) and “drug$” or 
“therapy” or “treatment”. These terms were combined in vari-
ous ways to generate a wide search. In addition, we checked 
references of eligible articles for further papers that were not 
captured by our search strategy and corresponded with authors 
when a full-length article was not available directly on-line or 
when relevant information was missing in the paper.
Inclusion criteria
We included articles that met the following pre-determined 
criteria: a) clinical trials performed in pediatric patients 
reporting on efficacy of omeprazole for the treatment of 
erosive esophagitis and gastroesophageal reflux in children, 
b) only delayed release omeprazole as oral suspension: ie, 
powder for oral suspension (Prilosec) or capsule content 
in liquid vehicle or non-encapsulated intact enteric-coated 
granules administered with fluids, c) studies in English lan-
guage, d) studies with adequate data about number and age 
of treated children, endoscopic diagnosis, total daily dose 
and duration of treatment.
Data extraction and synthesis
A form was generated to register whether individual studies 
met eligibility criteria and collect data regarding study design 
and methodological quality. Two investigators independently 
reviewed and extracted data from the papers according to the 
pre-determined criteria. Any differences in opinion about the 
studies were resolved by discussion between them.
Outcomes
Our analysis focused on the following measures of thera-
peutic efficacy: GERD symptom relief/resolution, reduction 
in reflux index, endoscopic and/or histological healing of 
esophagitis.
Analysis
Selection bias and lack of common outcome measures were 
some of the problems preventing a proper metanalysis. 
Therefore, we defined subgroups for the analysis by divid-
ing studies into 3 groups according to the outcome measures 
considered in each paper: a) GERD symptom relief/resolu-
tion, b) reduction in reflux scores as documented by 24-hour 
esophageal and/or gastric pH-monitoring, and c) endoscopic 
and/or histological healing of esophagitis.
Results
Our literature search identified 59 potentially relevant 
articles. After reviewing the titles and abstracts and the full-
length articles, 12 articles were selected for closer assessment 
and then included in our analysis.17,18,22,25–27,41–46 They are 
summarized in Table 1.
Of the 12 selected studies, 10 were controlled trials, 2 
were randomized controlled trials (1 was placebo-controlled41 
and the other compared omeprazole to ranitidine27). Ten 
were single-center studies, 2 were multi-center studies (1 of 
them was multinational42). Overall, data from a total of 262 
children were reported. Children’s age showed a wide range 
of variability ranging from 1.25 months to 18 years. The treat-
ment duration varied widely, ranging from 2 to 24 weeks, but 
after 2 weeks only intra-esophageal and/or gastric pH was 
evaluated in 2 studies17,41 and in 1 study also endoscopy was 
performed as early as within 2 weeks.22 The median dose of 
omeprazole was 1 mg/kg once daily (range 0.26–3.5 mg/kg). 
In all studies omeprazole was administered as a capsule or 
as the capsule content dispersed in a weakly acid vehicle, 
except for 2 studies17,18 where granules were dispersed in 
non-acid vehicles.
In general all the studies had similar aims, but some 
had different approaches, and consequently slightly 
different results. In the study by Cucchiara et al27 omeprazole 
decreased clinical score by 83%, improved histological 
and endoscopic degree of esophagitis by 75% and 82%, Clinical and Experimental Gastroenterology 2010:3 20
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Table 1 Clinical trials testing delayed-release omeprazole in children
 Author  
 
Study design 
 
Trial data 
(country, 
center)
No of 
treated 
children
Age 
 
Formulation 
 
Dosage 
 
Duration 
of therapy 
Measured 
parameters 
Cucchiara27 RCT Italy, 
single-center
12 6 mo–13.4 y capsule content 
or capsule
40 mg/1.73 
m2/die
8 wk symptoms, 
  esophageal 
and gastric pH 
  monitoring, 
endoscopic and 
histological degree 
of esophagitis
Moore41 RCT,  
double-blind, 
  placebo 
  controlled, 
crossover
Australia, 
multi-center
15 3–12 mo microspheres in 
apple juice
5–10 kg:  
10 mg/die;  
10 kg:  
10 mg/bid
2 wk symptoms, 
  esophageal pH 
monitoring
Hassal42 CT, open-label Multinational, 
multi-center
57 1–16 y capsule or  
granules in 
weakly acid 
vehicle for 
children unable 
to swallow intact 
capsule
0.7–3.5 mg/
kg/die
12 wk symptoms, 
  endoscopic degree 
of esophagitis
Alliët18 CT, open-label Belgium, 
single-center
12 2–3.8 mo capsule content 
in milk or water
0.5 mg/kg/ 
die = 20 mg/ 
1.73 m2/die
6 wk symptoms, gastric 
pH monitoring, 
endoscopic and 
histological degree 
of esophagitis
Bishop17 CT, open-label UK, 
single-center
10 1.25–20 mo multiple unit 
pellet system 
  dissolved in 
alkaline vehicle
0.7–2.8 mg/
kg/die
2 wk symptoms, 
  esophageal 
and gastric pH 
  monitoring
Cucchiara43 CT, open-label Italy, 
single-center
22 19 mo–12 y content of the 
  capsule in acid 
vehicle as
grapefruit or 
orange juice
1 mg/kg/ 
die = 40 mg/ 
1.73 m2/die
8 wk symptoms, 
  endoscopic degree 
of esophagitis
Kato22 CT, open-label Japan, 
single-center
5 3–18 y enteric coated 
preparation
0.3–1.6 mg/
kg/die
2–8 wk symptoms, gastric 
pH monitoring, 
endoscopic degree 
of esophagitis
De Giacomo44 CT, open-label Italy, 
single-center
10 2–9 y capsule content 30 kg:  
20 mg/die;  
30 kg:  
40 mg/bid
12 wk symptoms, 
  esophageal pH 
monitoring, 
endoscopic and 
histological degree 
of esophagitis
Karjoo45 CT, open-label USA, 
single-center
38 6–18 y capsule content 20–60 mg/die 8 wk symptoms
Gunasekaran25 CT, open-label Canada, 
single-center
15 0.8–17 y capsule or  
granules in 
weakly acid 
vehicle for 
children unable 
to swallow intact 
capsule
0.7–3.3 mg/ 
kg/die = 
10–60 mg/die
24 wk symptoms, 
  esophageal pH 
monitoring, 
  endoscopic degree 
of esophagitis
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  respectively, and reduced esophageal acid exposure by 61.9% 
and intra-gastric acidity by 29%. Moore et al41 reported 
significant reduction in reflux index without a significant 
reduction in irritability, which was the only evaluated 
  symptom. In the study by Hassal et al42 omeprazole healed 
endoscopic esophagitis in 95% of children and improved 
reflux symptoms in 91.5% even in the unhealed children. 
Alliet et al18 reported symptom improvement in 67%, endo-
scopic healing in 100% and histological healing in 67% of 
children and a significant reduction of intra-gastric acidity. 
Bishop et al17 reported a significant improvement both 
in reflux index and intra-gastric acidity and a significant 
improvement in clinical score in children younger than 
2 years. In another study Cucchiara et al43 reported symptom 
resolution or improvement in all patients and improvement 
in the endoscopic degree of esophagitis in 76% of cases. 
Kato et al22 reported symptom improvement in all children, 
endoscopic healing of esophagitis in 80% of children and 
significant reduction of intra-gastric acidity. De Giacomo 
et al44 showed endoscopic, but not histological, healing of 
esophagitis in 90% of treated children, symptoms improve-
ment in 100% and a significant reduction in reflux index. 
Karjoo et al45 reported symptom improvement in 87% of 
treated children. Gunasekaran et al25 reported symptom 
resolution, esophageal acid exposure within normal range 
and endoscopic healing of esophagitis in 100% of children 
by 6 months of treatment. Boccia et al46 reported endoscopic 
healing of esophagitis in 96% of children and symptom reso-
lution in 35%. Strauss et al26 showed symptom resolution or 
improvement in 100%, histological healing of esophagitis in 
37.5% and endoscopic healing in 100% of children.
For the purpose of our analysis, the studies were 
divided in subgroups according to the outcome parameters 
  measured. Table 2 shows esophageal and gastric pH-
monitoring, Table 3 shows endoscopic and histological 
results, and Figure 1 shows percentage of asymptomatic 
children after treatment.
All studies evaluated symptom relief/resolution, even if 
the symptoms considered and the scores used to graduate 
their presence/intensity were not homogeneous. GERD 
symptom improvement or disappearance were reported as 
percentage of asymptomatic children in 10 studies18,22,25–27,42–46 
and showed symptomatic response in 189 out of 235 treated 
children (80.4%) but rate of symptom relief widely varied 
ranging from 35% to 100% (Figure 1). In 2 studies17,41 the 
clinical score only was reported, and was significantly 
decreased in 1 study.17
Five studies17,25,27,41,44 evaluated reduction of esophageal 
reflux index, 4 studies17,18,22,27 measured reduction of intra-
gastric acidity (2 of them monitored both the esophageal 
and the gastric pH). Out of these 5 studies analyzing the 
esophageal 24-hour pH profile, 4 were comparable since 
they reported homogeneous data, ie, the median percentage 
of time of esophageal pH  4 (reflux index) before and 
after omeprazole treatment. In all studies reflux index was 
significantly decreased and was always within normal limits 
(ie, 7%) ranging from 1% to 5.4%. Out of the 4 studies mea-
suring reduction of intra-gastric acidity, 3 were comparable 
since they homogeneously reported the median percentage 
of time of gastric pH  4 both before and after treatment. 
Percentage of time of gastric pH  4 significantly decreased 
from 20% to 69%.
Table 1 (Continued)
Author 
 
Study design 
 
Trial data 
(country, 
center)
No. of 
treated 
children
Age 
 
Formulation 
 
Dosage 
 
Duration 
of therapy 
Measured 
parameters 
Boccia46 CT,  
open-label
Italy, 
single-center
48 2.7–14.2 y capsule or 
granules in 
weakly acid 
vehicle for 
children unable 
to swallow  
intact capsule
1.4 mg/kg/die 12 wk symptoms, 
  endoscopic 
degree of 
esophagitis
Strauss26 CT,  
open-label
USA, 
single-center
18 2–17 y capsule content 0.26–1.35 mg/
kg/die
8–12 wk symptoms, 
  endoscopic 
and histo-
logical degree of 
esophagitis
Abbreviations: CT, controlled trial; die, once daily; RCT, randomized controlled trial.Clinical and Experimental Gastroenterology 2010:3 22
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Nine studies evaluated the rate of healing of esophagitis 
in term of endoscopic healing18,22,25–27,42–44,46 and in 4 of them 
histological healing was also evaluated.18,26,27,44 For the purpose 
of our analysis, we considered as endoscopically healed a 
macroscopically normal esophageal mucosa, corresponding to 
grades 0 and 1 of Hetzel and Dent scale.47 According to this cri-
terion, patients presenting a grade 1 esophagitis at baseline were 
excluded from the calculation for the healing rate. The majority 
of children where endoscopic healing was reported were treated 
for 12 weeks or longer and healing tended to be better than in 
children treated for 8 weeks or less (P = 0.053). Histological 
healing was defined according to different criteria, so results 
were non comparable and we analyzed only the percentage of 
children reported as histologically healed. Overall the histo-
logical healing rate was significantly lower than the endoscopic 
healing in these 4 studies (49% vs 91%, P = 0.0001).
Discussion
In this review evidences about the efficacy of omeprazole 
treatment for esophagitis in children have been systematically 
reviewed. Efficacy has been evaluated in terms of symptom 
relief, normalization or improvement of gastric and/or 
esophageal acidity, and endoscopic and/or histological heal-
ing of esophagitis.
In 10 of 12 studies omeprazole was very effective 
in improving or resolving GERD symptoms, both when 
evaluated as a percentage of asymptomatic children or as a 
decreased symptom score. However, in 2 studies efficacy on 
symptoms was lower, particularly on irritability. Moore et al41 
reported that omeprazole did not significantly reduce irrita-
bility score in infants. However, irritability being evaluated 
by subjective methods, such as a diary of crying and fussing 
time and a visual analogue score of parental impression of 
its intensity was the only symptom evaluated. And when 
efficacy on reducing esophageal pH was assessed even in 
these infants a significant reduction in reflux index was seen. 
Similarly Boccia et al46 reported a low symptom resolution 
rate of 35%. However, analyzing each reported symptom 
even in this study irritability was the only non-improving 
one, whereas frequency of other symptoms like vomiting, 
Table 2 Studies evaluating esophageal and/or gastric pH-monitoring
Author   No of treated 
children
Esophageal pH-monitoring 
% of time of esophageal pH  4
Gastric pH-monitoring % of time 
of gastric pH  4
Cucchiara27 12 before treatment 9 after treatment 
3.1 D –5.9
before treatment 90.3 after treatment 
60.3 D –30
Moore41 15 before treatment 9.9 after 
treatment 1 D -8.9
Alliët18 12 before treatment 90.3 after treatment 
21.3 D –69
Bishop17 10 before treatment 18.5 after 
treatment 1.6 D –16.9
before treatment 71.9 after treatment 
13.2 D –58.7
Kato22 5 after treatment 72.2
De Giacomo44 10 before treatment 17 after treatment 
5.4 D –11.6
Gunasekaran25   15  before treatment range 11–88 after 
treatment 6
  
Table 3 Studies evaluating rates of endoscopic and/or histological healing of esophagitis
Author Duration of therapy Endoscopic healing Histological healing
Cucchiara27 8 wk 9/11 (82%) 9/12 (75%)
Hassal42 12 wk 54/57 (95%)
Alliët18 6 wk 12/12 (100%) 8/12 (67%)
Cucchiara43 8 wk 13/17 (76%)
Kato22 2–8 wk 4/5 (80%)
De Giacomo44 12 wk 9/10 (90%) 0/10
Gunasekaran25 24 wk 6/6 (100%)
Boccia46 12 wk 46/48 (96%)
Strauss26 8–12 wk 1/1 (100%) 6/14 (43%)
Notes: In 115 of 121 children treated for 12 weeks or longer endoscopic healing rate was 95% (95% CI 89–98). In 38 of 45 children treated for 8 weeks or shorter endoscopic 
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Omeprazole for erosive esophagitis and gastroesophageal reflux disease in children Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
heartburn, epigastric pain, and dysphagia significantly 
decreased. Therefore, the failure of omeprazole in treating 
irritability, despite effective acid suppression and significant 
efficacy on other symptom improvement, may be explained 
by the hypothesis that some infants/children could be irritable 
because of non-acid reflux or irritability could be a self-
  limiting condition tending to improve only over time.
The efficacy of omeprazole in suppressing acid out-
put has been demonstrated by esophageal17,25,27,41,44 and/or 
gastric17,18,22,27 pH monitoring or both.17,27 In particular, all 
the studies analyzing esophageal pH-monitoring showed 
an effective acid suppression by omeprazole, reducing the 
percentage of time of esophageal pH  4 to less than 6%, a 
reflux index 7% being considered abnormal according to 
recent guidelines of North American and European Society 
for Pediatric Gastroenterology.48
Omeprazole resulted to be very effective in healing 
esophagitis in children. Although data are analyzed in dif-
ferent way from studies performed in adults, and so results 
are not completely comparable, efficacy in children seems to 
be better than in adults. Indeed, a recent systematic review49 
reported the overall endoscopic healing for omeprazole in 
adults of 73.8% (95% CI 71–76) and in our children treated 
for 8 weeks or less was similar (84%, 95% CI 71–93) but 
in those treated for 12 weeks or longer healing rate was sig-
nificantly higher (95%, 95% CI 89–98). The possible better 
efficacy of omeprazole in children might be due to the higher 
dosage used in children, in whom doses of omeprazole are 
given on a per kilogram basis; or, alternatively, to a lesser 
severity of the inflammatory changes due to a shorter duration 
of the reflux disease in the younger population. However, 
when analyzed, the histological healing even in children 
was significantly lower, and in 2 studies26,44 histological 
parameters did not correlate with endoscopic healing or 
symptomatic relief.
Comparing omeprazole with other most common drugs 
or surgical approaches used for GERD and esophagitis treat-
ment in children, omeprazole seem to be more effective. Most 
of the children successfully treated with omeprazole included 
in this review were unresponsive to previous medical treat-
ments with anti-acids, H2-receptor blockers, pro-kinetic 
agents or surgery. However, when looking more carefully 
at the data presented the higher efficacy of omeprazole com-
pared to ranitidine is not proven. Karjoo et al45 initially treated 
children with 8 mg/kg once daily ranitidine, increasing to 
12 mg/kg once daily if no symptomatic improvement was 
observed after 2 weeks, but this apparent failure of ranitidine 
could be due to a too short period of observation or, more 
probably, to a too low dosage of ranitidine. Indeed, when 
Cucchiara et al27 directly compared omeprazole 1 mg/kg 
once daily to ranitidine at the dose of 20 mg/kg once daily 
efficacy was similar in symptom relief, endoscopic and 
Cucchiara27
Cucchiara43
Hassall42
Alliët18
Kato22
De Giacomo44
Karjoo45
Gunasekaran25
Boccia46
Strauss26
10 of 12 children
43 of 47 children
8 of 12 children
22 of 22 children
5 of 5 children
10 of 10 children
33 of 38 children
15 of 15 children
17 of 48 children
16 of 16 children
0 10 20 30 40 50 60 70 80 90 100
Figure 1 Symptom resolution rates in the 10 studies reporting percentage of asymptomatic children after treatment.Clinical and Experimental Gastroenterology 2010:3 24
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histological healing, and in reducing esophageal and gastric 
acidity, whereas the same children previously treated with 
ranitidine at the dosage of 8 mg/kg once daily had not 
responded. Dosage of ranitidine is known to correlate with 
the esophageal reflux index and a dose lower than 10 mg/kg 
dail is indeed ineffective to heal esophagitis.50 However, data 
on the similarity of ranitidine and omeprazole efficacy in the 
treatment of childhood esophagitis are insufficient and other 
head-to-head studies are necessary, particularly because in 
adults omeprazole was reported to have a superior efficacy 
to H2-receptor blockers in treating esophagitis.51
Similarly, data on usefulness of maintenance therapy or 
in-demand therapy for prevention of recurrence in children 
are insufficient. Only in 1 study46 were children followed after 
healing and maintenance therapy for longer enough to assess 
prevalence of relapse and found symptoms recurrence only 
in 6.8% of children even after maintenance discontinuation, 
unsupporting the necessity of maintenance therapy.
Conclusion
In conclusion, delayed-release oral suspension of omepra-
zole given at a median dosage of 1 mg/kg once daily for a 
median duration of 12 weeks showed high efficacy in treat-
ing GERD and esophagitis in children. Moreover, thanks to 
its safety and tolerability omeprazole use in childhood can 
be extended to clinical settings. The need for a long-term 
maintenance therapy, however, is still to be assessed in the 
pediatric population.
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